利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.049 秒)

    Methods, compositions and articles for reducing or preventing the effects of inflammation
    11.
    发明授权
    Methods, compositions and articles for reducing or preventing the effects of inflammation 失效
    用于减少或预防炎症作用的方法，组合物和制品

    公开(公告)号：US06274614B1

    公开(公告)日：2001-08-14

    申请号：US08942883

    申请日：1997-10-02

    申请人： Anna M. Richter ,  Julia G. Levy ,  Claude A. A. Hariton ,  Gustave Huber ,  William C. Stewart ,  Mario G. Fsadni

    发明人： Anna M. Richter ,  Julia G. Levy ,  Claude A. A. Hariton ,  Gustave Huber ,  William C. Stewart ,  Mario G. Fsadni

    IPC分类号： A61K3140

    CPC分类号： A61K41/0071 ,  Y10S514/912 ,  Y10S514/913

    摘要： A method for reducing or preventing the effects of inflammation arising from injured tissue, which method comprises the steps of: a. bringing the injured tissue, or pre-injured tissue, into contact with a photosensitizing agent capable of penetrating into the tissue, resulting in the desired degree of biodistribution in less than one hour; and b. exposing the tissue thus contacted to light having a wavelength absorbed by the photosensitizing agent for a time sufficient to reduce or prevent inflammation in the exposed tissue, but not so long as to cause necrosis or erythema of the exposed tissue, or a pharmaceutical composition or an article for reducing or preventing the effects of inflammation arising from injured tissue. The composition comprises: a. from about 1 &mgr;/mL to about 2 mg/mL of a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution less than one hour; and b. a pharmaceutically acceptable carrier. The article comprises: a. a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution in less than one hour, and b. an absorbent applicator.

    摘要翻译： 一种减少或防止受损组织引起的炎症影响的方法，该方法包括以下步骤：a。 使损伤的组织或预损伤的组织与能够渗透到组织中的光敏剂接触，在少于1小时内产生所需程度的生物分布; 安布 将由此与光敏剂吸收的波长接触的组织暴露于足以减少或防止暴露组织中的炎症的时间，但不会导致暴露组织的坏死或红斑，或药物组合物或 用于减少或预防由损伤组织引起的炎症影响的制品。组合物包括：a。 约1μg/ mL至约2mg / mL的能够渗透到损伤组织或预损伤组织的光敏剂，导致所需程度的生物分布小于1小时; 安布 药学上可接受的载体。 以及能够渗透到受损组织或预损伤组织中的光敏剂，在不到一小时内产生所需程度的生物分布，和b。 吸收性涂抹器。

    Method for reducing or preventing PDT related inflammation
    13.
    发明授权
    Method for reducing or preventing PDT related inflammation 有权
    降低或预防PDT相关炎症的方法

    公开(公告)号：US08106038B2

    公开(公告)日：2012-01-31

    申请号：US10081010

    申请日：2002-02-15

    申请人： Philippe Maria Clotaire Margaron ,  Anna M. Richter ,  Julia G. Levy

    发明人： Philippe Maria Clotaire Margaron ,  Anna M. Richter ,  Julia G. Levy

    IPC分类号： A61K31/55

    CPC分类号： A61K41/0057 ,  A61K41/0071 ,  Y10S514/912

    摘要： This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy (“PDT”). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.

    摘要翻译： 本发明一般涉及药物治疗领域和光动力疗法（“PDT”）的使用。 特别地，本发明提供了减少或预防由正常剂量光动力治疗（PDT）引起的炎症影响的方法，该方法包括将已经用正常剂量PDT治疗的受试者中的靶组织暴露于具有 由在所述正常剂量PDT处理中使用的光敏剂吸收的波长足以减少或防止由所述正常剂量PDT处理引起的炎症的影响的时间。 该方法特别可用于减少或预防由正常剂量PDT治疗眼组织引起的炎症的作用。

    Benzoporphyrin derivatives for photodynamic therapy
    15.
    发明授权
    Benzoporphyrin derivatives for photodynamic therapy 失效
    苯并卟啉衍生物用于光动力疗法

    公开(公告)号：US5214036A

    公开(公告)日：1993-05-25

    申请号：US491674

    申请日：1990-03-08

    申请人： Beth A. Allison ,  Anna M. Richter ,  P. Haydn Pritchard ,  Julia G. Levy

    发明人： Beth A. Allison ,  Anna M. Richter ,  P. Haydn Pritchard ,  Julia G. Levy

    IPC分类号： A61K31/40 ,  A61K41/00

    CPC分类号： A61K41/0071 ,  A61K31/40

    摘要： Green porphyrins (Gp), compounds important in photodynamic therapy, have been associated with lipocomplexes to reduce the required amount of photosensitizer through higher effective absorption and increased specificity. BPDs, especially in conjunction with the HDL fraction of plasma lipoproteins, has been shown to be particularly effective in this context. Pharmaceutical compositions in which these combinations are the active ingredients for use in diagnosis and treatment of tumors are also disclosed.

    摘要翻译： 绿光卟啉（Gp）是光动力学治疗中重要的化合物，与脂质复合物有关，通过更高的有效吸收和增加的特异性降低所需量的光敏剂。 BPD，特别是与血浆脂蛋白的HDL分数结合已被证明在这方面特别有效。 还公开了这些组合是用于诊断和治疗肿瘤的活性成分的药物组合物。

    Methods, compositions and articles for reducing or preventing the effects of inflammation
    16.
    发明授权
    Methods, compositions and articles for reducing or preventing the effects of inflammation 有权
    用于减少或预防炎症作用的方法，组合物和制品

    公开(公告)号：US06677366B2

    公开(公告)日：2004-01-13

    申请号：US09929558

    申请日：2001-08-13

    申请人： Anna M. Richter ,  Julia G. Levy ,  Claude A. A. Hariton ,  Gustave Huber ,  William C. Stewart ,  Mario G. Fsadni ,  Modestus O. K. Obochi

    发明人： Anna M. Richter ,  Julia G. Levy ,  Claude A. A. Hariton ,  Gustave Huber ,  William C. Stewart ,  Mario G. Fsadni ,  Modestus O. K. Obochi

    IPC分类号： A61K3140

    CPC分类号： A61K41/0071 ,  Y10S514/912

    摘要： A method for reducing or preventing the effects of inflammation arising from injured tissue, which method comprises the steps of: a. bringing the injured tissue, or pre-injured tissue, into contact with a photosensitizing agent capable of penetrating into the tissue, resulting in the desired degree of biodistribution in less than one hour; and b. exposing the tissue thus contacted to light having a wavelength absorbed by the photosensitizing agent for a time sufficient to reduce or prevent inflammation in the exposed tissue, but not so long as to cause necrosis or erythema of the exposed tissue, or a pharmaceutical composition or an article for reducing or preventing the effects of inflammation arising from injured tissue. The composition comprises: a. from about 1 &mgr;g/mL to about 2 mg/mL of a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution less than one hour; and b. a pharmaceutically acceptable carrier. The article comprises: a. a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution in less than one hour; and b. an absorbent applicator.

    摘要翻译： 一种减少或防止受损组织引起的炎症影响的方法，该方法包括以下步骤：a。 使损伤的组织或预损伤的组织与能够渗透到组织中的光敏剂接触，在少于1小时内产生所需程度的生物分布; 安布 将由此与光敏剂吸收的波长接触的组织暴露于足以减少或防止暴露组织中的炎症的时间，但不会导致暴露组织的坏死或红斑，或药物组合物或 用于减少或预防由损伤组织引起的炎症影响的制品。组合物包括：a。 约1ml / mL至约2mg / mL的能够渗入损伤组织或预损伤组织的光敏剂，导致所需程度的生物分布小于1小时; 安布 药学上可接受的载体。 能够渗入损伤组织或预损伤组织的光敏剂，在少于1小时内产生所需程度的生物分布; 安布 吸收性涂抹器。

    Method of activating photosensitive agents
    19.
    发明授权
    Method of activating photosensitive agents 失效
    激活光敏剂的方法

    公开(公告)号：US5705518A

    公开(公告)日：1998-01-06

    申请号：US391414

    申请日：1995-02-16

    申请人： Anna M. Richter ,  Elizabeth Waterfield ,  Julia G. Levy

    发明人： Anna M. Richter ,  Elizabeth Waterfield ,  Julia G. Levy

    IPC分类号： A61K41/00 ,  A61N5/06 ,  A61P35/00 ,  A61K31/41

    CPC分类号： A61N5/062 ,  A61K41/0071

    摘要： A method of administering photodynamic therapy begins with administering to an animal an effective amount of a photosensitizing agent which is less than about one half of the usual clinical dose for the photosensitizing agent. Then, following a post injection interval which is less about one quarter of the usual post injection interval, an effective dose of light which is less than about one half of the usual clinical dose of light used in conjunction with the photosensitizing agent is administered to the animal.

    摘要翻译： 施用光动力学治疗的方法开始于向动物施用有效量的光敏剂，其光敏剂的常用临床剂量的一半以下的一半以下。 然后，在后注射间隔小于常规后注射间隔的四分之一的后注射间隔中，将与光敏剂结合使用的光的常规临床剂量小于约一半的有效剂量给予 动物。